

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 71, ISSUE 4, PAGES 641–852

FROM THE EDITOR'S DESK

From the Editor's Desk...

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 641

EDITORIALS

Excellence in viral hepatitis elimination – Lessons from Georgia

F. Averbhoff, J.V. Lazarus, D. Sergeenko, M. Colombo, A. Gamkrelidze, T. Tsertsvadze, M. Butashvili, D. Metreveli, L. Sharvadze, M. Hellard, S. Gnes, T. Gabunia and M. Nasrullah 645

Paving the way for T cell-based immunotherapies in chronic hepatitis E

C. Neumann-Haefelin 648

iLFT: A big assist in the recognition of liver disease in general practice

A.C. Cheung and P.Y. Kwo 651

Allocation of deceased-donor livers – Is there a most appropriate method?

J. Neuberger and J.K. Heimbach 654

Bile acid metabolism and T cell responses in cholangiopathy: Not one-way traffic

S. Shetty and J.L. Boyer 657

RESEARCH ARTICLES

Viral Hepatitis

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

S.M. Borgia, J. Dearden, E.M. Yoshida, S.D. Shafran, A. Brown, Z. Ben-Ari, M.E. Cramp, C. Cooper, M. Foxton, C.F. Rodriguez, R. Esteban, R. Hyland, S. Lu, B.J. Kirby, A. Meng, S. Markova, H. Dvory-Sobol, A.O. Osinusi, R. Bruck, J. Ampuero, S.D. Ryder, K. Agarwal, R. Fox, D. Shaw, S. Haider, B. Willems, Y. Lurie, J.L. Calleja and E.J. Gane 660

Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

J. Llaneras, M. Riveiro-Barciela, S. Lens, M. Diago, A. Cachero, J. García-Samaniego, I. Conde, A. Arencibia, J. Arenas, F. Gea, X. Torras, J. Luis Calleja, J. Antonio Carrión, I. Fernández, R. María Morillas, J.M. Rosales, I. Carmona, C. Fernández-Rodríguez, M. Hernández-Guerra, S. Llerena, V. Bernal, J. Turnes, J.M. González-Santiago, S. Montoliu, B. Figueruela, E. Badía, M. Delgado, M. Fernández-Bermejo, M. Iñarrairaegui, J.M. Pascasio, R. Esteban, Z. Mariño and M. Buti 666

Defining virus-specific CD8⁺ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E

C.F. Soon, P. Behrendt, D. Todt, M.P. Manns, H. Wedemeyer, M. Sällberg Chen and M. Cornberg 673

MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance

S. Yang, L. Wang, W. Pan, W. Bayer, C. Thoens, K. Heim, U. Dittmer, J. Timm, Q. Wang, Q. Yu, J. Luo, Y. Liu, M. Hofmann, R. Thimme, X. Zhang, H. Chen, H. Wang, X. Feng, X. Yang, Y. Lu, M. Lu, D. Yang and J. Liu 685

Cirrhosis

Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care

J.F. Dillon, M.H. Miller, E.M. Robinson, A. Hapca, M. Rezaeihehemi, C. Weatherburn, P.G. McIntyre, B. Bartlett, P.T. Donnan, K.A. Boyd and E. Dow 699

Transplantation

Allocation of liver grafts worldwide – Is there a best system?

C. Tschuor, A. Ferrarese, C. Kuemmerli, P. Dutkowski, P. Burra, P.-A. Clavien and on behalf of the Liver Allocation Study Group 707

Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury

Y. Liu, T. Lu, C. Zhang, J. Xu, Z. Xue, R.W. Busuttil, N. Xu, Q. Xia, J.W. Kupiec-Weglinski and H. Ji 719

Cancer

TOX promotes the exhaustion of antitumor CD8⁺ T cells by preventing PD1 degradation in hepatocellular carcinoma

X. Wang, Q. He, H. Shen, A. Xia, W. Tian, W. Yu and B. Sun 731

Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis

J. Wang, H. Wang, M. Peters, N. Ding, S. Ribback, K. Utpatel, A. Cigliano, F. Dombrowski, M. Xu, X. Chen, X. Song, L. Che, M. Evert, A. Cossu, J. Gordan, Y. Zeng, X. Chen and D.F. Calvisi 742

Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules

G. Zhou, D. Sprengers, S. Mancham, R. Erkens, P.P.C. Boor, A.A. van Beek, M. Doukas, L. Noordam, L. Campos Carrascosa, V. de Ruiter, R.W.F. van Leeuwen, W.G. Polak, J. de Jonge, B. Groot Koerkamp, B. van Rosmalen, T.M. van Gulik, J. Verheij, J.N.M. IJzermans, M.J. Bruno and J. Kwekkeboom 753

Molecular and Cell Biology

Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis

M. Bonnin, N. Fares, B. Testoni, Y. Estornes, K. Weber, B. Vanbervliet, L. Lefrançois, A. Garcia, A. Kfoury, F. Pez, I. Coste, P. Saintigny, A. Viari, K. Lang, B. Guey, V. Hervieu, B. Bancel, B. Bartoch, D. Durantel, T. Renno, P. Merle and S. Lebecque 763

Cholestasis and Autoimmune Diseases

Interferon- γ -dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice

G. Ravichandran, K. Neumann, L.K. Berkhout, S. Weidemann, A.E. Langeneckert, D. Schwinge, T. Poch, S. Huber, B. Schiller, L.U. Hess, A.E. Ziegler, K.J. Oldhafer, R. Barikbin, C. Schramm, M. Altfeld and G. Tiegs 773

Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis

F. Glaser, C. John, B. Engel, B. Höh, S. Weidemann, J. Dieckhoff, S. Stein, N. Becker, C. Casar, F.A. Schuran, B. Wieschendorf, M. Preti, F. Jessen, A. Franke, A. Carambia, A.W. Lohse, H. Ittrich, J. Herkel, J. Heeren, C. Schramm and D. Schwinge 783

Genetic and Metabolic Diseases

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Z.M. Younossi, P. Golabi, L. de Avila, J.M. Paik, M. Srishord, N. Fukui, Y. Qiu, L. Burns, A. Afendy and F. Nader 793

Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease

V. Nobili, A. Mantovani, S. Cianfarani, A. Alisi, A. Mosca, M.R. Sartorelli, C. Maffei, R. Loomba, C.D. Byrne and G. Targher 802

REVIEWS

News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document

P. Angelí, G. Garcia-Tsao, M.K. Nadim and C.R. Parikh 811

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

M.E. Rinella, F. Tacke, A.J. Sanyal, Q.M. Anstee and of the participants of the AASLD/EASL Workshop 823

CASE REPORT

Excellent safety and effectiveness of high-dose myrcyludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients

A. Loglio, P. Ferenci, S.C. Uceda Renteria, C.Y.L. Tham, F. van Bömmel, M. Borghi, H. Holzmann, R. Perbellini, E. Trombetta, S. Giovanelli, L. Greco, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, A. Bertoletti and P. Lampertico 834

LETTERS TO THE EDITOR

A novel score to select patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort

A. Johannessen, H. Aberra, H. Desalegn, E. Gordien and N. Berhe 840

Performance of two simplified HBV treatment criteria (TREAT-B score and WHO guidelines) in Burkina Faso, West Africa

Y. Shimakawa, P. Boucheron, L.B. Luong Nguyen, M. Lemoine and R. Sombié 842

Another clinical unmet need in liver patients: Multidrug resistant bacteria in decompensated cirrhosis

R. Morais, R. Liberal, A. Santos, I. Pita, R. Coelho, R. Gaspar, A. Andrade, H. Cardoso, S. Rodrigues and G. Macedo 844

Reply to: "Another clinical unmet need in liver patients: Multidrug-resistant bacteria in decompensated cirrhosis"

M. Hernández-Tejero, M. Triolo and J. Fernández 845

Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction

J. Choi and Y.-S. Lim 846

Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction"

B.K. Kim 847

Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges

L. Valenti, S. Pelusi and G. Baselli 849

Reply to: "Whole exome sequencing for personalized hepatology: Expanding applications in adults and challenges"

A. Hakim, P.K. Mistry and S. Vilarinho 850

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care, by John F. Dillon et al. on pp. 699–706 in this issue.

Cover design: The illustration represents the assessment of the liver function, with the integration of clinical and biochemical data, under computer control, background image by © deepagopi2011 – stock.adobe.com, artwork composite by Pablo Echeverria.